

DRIVE RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

November 2016

Remember: Clicking the **coloured links** will take you to more information!



Don't forget: DRIVE-AB is on **Twitter!** Don't miss out - follow us at [@DRIVE_AB](https://twitter.com/DRIVE_AB).

Interested in getting involved? Just go to our website and click "**Stakeholder Engagement**" to find out all you need to know about getting involved with the project!

Or, fill out our **Expression of Interest Form** for stakeholders to let us know exactly how you or your organization would like to engage with the project. Please share this newsletter with other interested stakeholders as well!

DRIVE-AB General Assembly

The annual **General Assembly of DRIVE-AB partners** took place from 17 to 18 October in Oslo, Norway. The group discussed project achievements, challenges, and next steps for the final year of DRIVE-AB. Keynote speeches were also presented by special guests the **Duke-Margolis Center for Health Policy** and the **Norwegian Institute of Public Health** to discuss their work on stimulating antibiotic R&D and ensuring sustainable use, respectively. Please click here to view the **Agenda: DRIVE-AB General Assembly 2016**.



Conference Report Available: Stimulating innovation, sustainable use and global access to antibiotics: Conference Report

A **full conference report** detailing the discussions and outputs of this year's **DRIVE-AB high-level conference** in Amsterdam on 2 June, has been released. The conference brought together over 180 policy makers, regulatory and public health experts, economists and research and industry experts to identify and evaluate reward models that are feasible, practical and can be implemented globally. **Click here to read the full conference report.** To see more conference materials, including the

programme, an executive summary and a detailed outline of the reward models that were discussed, [please see our website](#).



DRIVE-AB Referenced in a Report of the UN Secretary-General

Last month DRIVE-AB was referenced in the [Report of the UN Secretary-General's High-Level Panel on Access to Medicines: Promoting innovation and access to health technologies](#), as a project working to develop economic stimulants for antibiotic R&D.

Additional recent DRIVE-AB outputs

- [Publication: “The global definition of responsible antibiotic use: The DRIVE-AB project”](#)
AMR Control 2016 article by DRIVE-AB partners V. Zanichelli, B. Huttner and S. Harbarth. 12 July 2016.
- [Policy Brief #3: “The importance of multinational coordination and increased public financing for antibiotic innovation”](#)
Developed for the [United Nations General Assembly meeting on antimicrobial resistance](#) in September 2016. Also disseminated at the [Global Health Security Agenda 3rd Annual Ministerial Meeting](#), October 2016.
- [Publication: “An assessment of the future impact of alternative technologies on antibiotics markets”](#)
Journal of Pharmaceutical Policy and Practice article by [Work Package 2](#). 26 October 2016.

To view all DRIVE-AB outputs to date, please see our website.

What have we been up to?



DRIVE-AB distributed a policy brief at a side event of the [United Nations General Assembly meeting](#) on antimicrobial resistance in September 2016 as well as the [Global Health Security Agenda 3rd Annual Ministerial Meeting](#) in October 2016. To date, DRIVE-AB has produced three policy briefs:

- Policy Brief 1: “The necessity for greater antibiotic innovation”
- Policy Brief 2: “The role for non-profit antibiotic developers”
- Policy Brief 3: “The importance of multinational coordination and increased public financing for antibiotic innovation”

DRIVE-AB took part in the [World Anti-Microbial Resistance Congress on 8-9 September in Washington, D.C.](#) DRIVE-AB co-coordinator Judith Hackett and consortium associate-partner Kevin Outterson both spoke at the event.



DRIVE-AB was well represented at the **Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID) 33rd Annual Meeting** which took place in Rovaniemi, Finland on 15-18 September 2016. **Communications** co-lead Ursula Theuretzbacher gave a speech, the slides for which can be found **on our website**.



DRIVE-AB Attended the United Nations General Assembly Meeting on Antimicrobial Resistance. Before convening for the meeting on 21 September all 193 Member States agreed a **declaration to combat the proliferation of antibiotic-resistant bacteria** through a global response similar to the framework used to combat climate change.



DRIVE-AB **Communications** co-lead Ursula Theuretzbacher presented at a side event to this year's **World Health Summit** on 11 October. **The presentation can be found on our website**.

Project updates by work package

Responsible use of antibiotics, new and old

In addition to publishing their article **“The global definition of responsible antibiotic use: The DRIVE-AB project”**, the team is preparing a series of articles to be published in the Journal of Antimicrobial Chemotherapy in individual issues throughout 2017. The definition of “responsible use” has been finalized and the team is actively engaging with stakeholders from a variety of backgrounds to help the group to evaluate the feasibility of their agreed metrics and indicators in different settings, identify how they can be applied in clinical settings, facilitate the implementation of antimicrobial stewardship policies and create educational materials. **To read a summary of their most recent stakeholder meeting on 28 September, please click here**. For more detailed information on the group’s progress or to register your interest in contributing to the survey, please see their **stakeholder engagement webpage**.

Setting, communicating and revising public health priorities

The team has completed the development of simulation models to predict transmission and spread of antibiotic-resistant bacteria globally, regionally and locally (within hospital). The models will be available free-of-charge online and can predict spread based on modifiable variables, which can be altered by the user to enhance the accuracy of predictions. Moving forward, the group is exploring the impact of tourism and medical tourism on MDR spread and working to generate rate and incidence data for key pathogens. The data that the team has generated will be used for evidence-based criteria for the World Health Organization Priority Pathogen List, which will be finalized by February 2017. For more detailed information on the group’s progress, please see their **stakeholder engagement webpage**.

Antibiotic Evaluation

The team has completed draft manuscripts on a framework for valuing antibiotics as well as lessons learned from the pre-antibiotic era and hopes to publish these soon. Stakeholder interviews and expert elicitation are currently underway to estimate the burden of antimicrobial resistance. The team is also planning a workshop with health technology assessment (HTA) stakeholders in early 2017 to discuss the possibilities of changing the HTA process for antibiotics. For more detailed information on the group’s progress or to register your interest in attending the stakeholder meeting, please see their **stakeholder engagement webpage**.

Creation and testing of new economic models

In addition to publishing their paper, **“An assessment of the future impact of alternative technologies on antibiotics markets”**, producing policy brief #3, **“The importance of**

multinational coordination and increased public financing for antibiotic innovation” and contributing to the development of the **“DRIVE-AB Conference Report”**, the team is working to further refine, assess and pilot test their shortlist of incentives and reward models to stimulate investment in antibiotic R&D. They are also designing and testing sustainable use and equitable availability policies. The team will begin writing their final report and the recommendations for implementation in the spring of 2017 along with two policy briefs which will be directed at the World Health Assembly and the G20 Presidency. For more detailed information on the group’s progress, please see their [stakeholder engagement webpage](#).

Project management and governance

Along with ongoing project monitoring and management activities, the team has successfully organized the annual **DRIVE-AB General Assembly**, held in October, and has been busy putting together the annual report to the IMI. For more detailed information on the group’s progress, please see the [website](#).

Stakeholder platform and external communication

In addition to the development and delivery of the **Conference Report**, the team has been working on updating the DRIVE-AB communications strategy. The team met with Work Package representatives in September to review and refine the strategy in response to the rapidly changing landscape of the antibiotic resistance field. The group also continues to manage project communications both internally and externally by monitoring and updating the website and social media and managing potential and novel stakeholders. For more detailed information on the group’s progress, please see the [website](#).

[Edit your subscription](#) | [Unsubscribe](#)